Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

312 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-04-30

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

NCT01025479

Prostate Cancer Osteoporosis

COMPLETED

Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer

NCT00003903

Osteoporosis Prostate Cancer

COMPLETED NA

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

NCT04248621

Prostatic Neoplasms

UNKNOWN PHASE4

Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

NCT00536653

Osteoporosis

COMPLETED NA

Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly

NCT00161252

Prostate Cancer

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

MC MD

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Total of 250 prostate cancer patients receiving GnRH agonist

No interventions assigned to this group

B

Total of 250 prostate cancer patients receiving GnRH agonist plus anti-androgen agent

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Korean prostate cancer over 50 years old with pathological confirmation
* Patients receiving GnRH antagonist or GnRH agonist plus anti- androgen combination within 6 months since starting.
* Patients measured bone density level before starting to receive hormone therapies above.

Exclusion Criteria

* Patients who are treated other anti-osteoporosis drugs and who are treated bisphosphate due to BMD T score below -3.0.
* Patients who are hard to be analysed by attach to other bone disease.
* Patients who are hard to be analysed by limitation of chart record according to investigators'discretion.

Minimum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No